Advancing gastroenterology, improving patient care

Similar documents
Primary Management of Irritable Bowel Syndrome

Current and Emerging Pharmacological Treatments in Irritable Bowel Syndrome

Xifaxan, Lotronex and Viberzi Prior Authorization and Quantity Limit Program Summary

IBS Irritable Bowel syndrome Therapeutics II PHCL 430

Is one of the most common chronic disorders. causing patients to seek medical treatment.

4) Irritable Bowel Syndrome - Dr. Shaikhani. Epidemiology. Pathophysiology. Burden. Diagnosis

Irritable Bowel Syndrome. Mustafa Giaffer March 2017

Disclosures. Objectives. Pre-Test Question 1. Pre-Test Question 2. Pre-Test Question 3 9/23/2016

Diagnosis and Management of Irritable Bowel Syndrome (IBS) For the Primary Care Provider

Irritable Bowel Syndrome. Paul Sheykhzadeh, DO, FACG Digestive Health Associates Reno, NV NAPNA Symposium March 5, 2016

Irritable Bowel Syndrome Now. George M. Logan, MD Friday, May 5, :35 4:05 PM


William D. Chey, MD Professor of Medicine University of Michigan

Presenter. Irritable Bowel Syndrome. Objectives. Introduction. Rome Criteria. Irritable Bowel Syndrome 2/28/2018

ROME IV CRITERIA FOR IBS

IBS. Dan Carter, M.D. Institute of Gastroenterology Sheba medical center

อภ ชาต แสงจ นทร ภาคว ชาอาย รศาสตร คณะแพทย ศาสตร มหาว ทยาล ยขอนแก น

Pharmacotherapy for IBS

American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome

Irritable Bowel Syndrome: Current and Emerging Treatment Options

The Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders What are functional GI disorders?

Inflammatory or Irritable? (the bowel, not the speaker)

IRRITABLE BOWEL SYNDROME

What is Irritable Bowel Syndrome (IBS)?

Irritable Bowel Syndrome

Diagnosis and Treatment of Irritable Bowel Syndrome

Management of Functional Bowel Disorders

Irritable Bowel Syndrome (IBS) Information Leaflet THE DIGESTIVE SYSTEM

The Leeds Teaching Hospitals NHS Trust Irritable Bowel Syndrome

Dr. Melvyn Letier Constantiaberg Mediclinic October 2016

Constipation an Old Friend. Presented by Dr. Keith Harris

Addendum to NICE guideline CG61, Irritable bowel syndrome in adults

IBS CLOSED REFERRAL STATUS: Dear Dr.,

Irritable bowel syndrome in adults

Treat primary. symptoms. Offer general lifestyle advice. Manage IBS according to the dominant symptom. Follow up. Symptoms do not improve

IBS and Functional GI Disorders (FGIDs)

Evolving Therapy in Irritable Bowel Syndrome (IBS)

Do Probiotics Provide Adequate Relief From Overall Symptoms, Including Abdominal Pain and Bloating, in Adults With Irritable Bowel Syndrome?

Amitiza. Amitiza (lubiprostone) Description

Irritable Bowel Syndrome (IBS)

Clinical guideline Published: 23 February 2008 nice.org.uk/guidance/cg61

IRRITABLE BOWEL SYNDROME

Current Pharmacological Treatment Options in Chronic Constipation and IBS with Constipation

Clinically proven to quickly relieve symptoms of common gastrointestinal disorders. TERRAGASTRO - Good health starts in the gut

Irritable Bowel Disease. Dr. Alexandra Ilnyckyj MD

Emerging Treatments for IBS-C and Clinical Trial Endpoints

Tenapanor for irritable bowel syndrome with constipation

Irritable Bowel Syndrome

Understanding and Managing IBS and CIC in the Primary Care Setting

IBS - Definition. Chronic functional disorder of GI generally characterized by:

4 mg QHS; 3 wks RCT double-blind Global Improvement:

Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS)

National Institute for Health and Care Excellence Surveillance programme

Appendix A: Summary of evidence from surveillance

Identify electrolytes that should be monitored whenever prolonged or severe diarrhea is present

Chronic constipation in the elderly

David Leff, DO. April 13, Disclosure. I have the following financial relationships to disclosure:

Why does my stomach hurt? Exploring irritable bowel syndrome

Irritable Bowel Syndrome and Chronic Constipation

Antidiarrheals Antidiarrheal

Delfini Group, LLC Evidence & Value based Solutions For Health Care Clinical Improvement Consults, Content, Seminars, Training & Tools

WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS

Tana's Habitat - Vim and Vigor - They Don t Call Them High Bars For Nothin

5 Things to Know About Irritable Bowel Syndrome

Disclosures. 4 th Annual Digestive Disease IBS: New Management Approaches. Early description of symptoms defining IBS 1849 W Cumming.

Evidence-based clinical practice guidelines for irritable bowel syndrome

10/10/16. Disclosures. Educational Objectives

Irritable Bowel Syndrome

What Is Constipation?

State of the Art: Management of Irritable Bowel Syndrome

Lower Gastrointestinal Tract KNH 406

Evidence and Recommendations for the Use of Prebiotics in Clinical Settings

Calming the Colon: A Review of Irritable Bowel Syndrome

Calming the Colon: A Review of Irritable Bowel Syndrome

PainReliefSciences.com 1

Review article: an analysis of safety profiles of treatments for diarrhoea predominant irritable bowel syndrome

National Naval Medical Center Bethesda, MD

Irritable bowel syndrome (IBS) is a chronic, potentially disabling

Chronic Pelvic Pain Case Study

Statement of Sponsorship and Support

UBS Global Healthcare Conference May 19, 2014

OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA

Chronic Abdominal Pain. Dr. Robert B. Smith Tupelo Digestive Health Specialists August 26, 2016

Irritable bowel syndrome in adults

Efficacy and Safety of Lubiprostone. Laura Wozniak February 23, 2010 K30 Monthly Journal Club

Antidepressant Medication use is Associated with Abdominal Symptoms in People without a Functional Gastrointestinal Diagnosis

See Important Reminder at the end of this policy for important regulatory and legal information.

Recent advances in pharmacological treatment of irritable bowel syndrome

NEL RISPETTO DELLE NUOVE DISPOSIZIONI IN MATERIA DI ECM, A SEGUITO DELL ATTUAZIONE DELL ACCORDO STATO-REGIONI DEL 5/11/09 E SUCCESSIVE

Irritable Bowel Syndrome and Chronic Constipation. Treatment of IBS. Susan Lucak, M.D. Columbia University Medical Center

Carminatives IBS C 11/12/10. Partial List of Carminatives and Secondary Benefits. Partial List of Carminatives and Secondary Benefits

William Chey, MD University of Michigan Ann Arbor, MI

CENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 2Q17 April May

An Evidence-based Approach to Irritable Bowel Syndrome. Robert Baldor, MD, FAAFP

Irritable bowel syndrome: A concise review of current treatment concepts

Factsheet LINACLOTIDE (Constella ) Irritable Bowel Syndrome constipation predominant (IBS-C)

Food is Medicine: A Nutritional Approach to IBS and More. Kathleen N. Mueller, M.D. CAFP Scientific Symposium 2017

Clinical Policy: Alosetron (Lotronex) Reference Number: CP.CPA.65 Effective Date: Last Review Date: Line of Business: Medicaid Medi-Cal

IRONWOOD AND FOREST ANNOUNCE POSITIVE LINACLOTIDE RESULTS FROM PHASE 3 TRIAL IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION

Transcription:

American College of Gastroenterology Advancing gastroenterology, improving patient care Note to Visitors: A fully updated ACG Systematic Review on the Management of Chronic Idiopathic Constipation and Irritable Bowel Syndrome will publish in 2014 as a supplement to The American Journal of Gastroenterology. This treatment matrix will be updated at that time. Linaclotide Linaclotide is a 14 amino acid peptide structurally similar to hormones in the guanylin peptide family. Guanylin peptides are endogenous hormones that assist in the regulation of intestinal fluid and electrolyte homeostasis by binding to, and activating, guanylate cyclase-c receptors on the lumen of intestinal epithelium. Linaclotide is superior to placebo for the treatment of constipation-predominant IBS with a high quality of evidence. Symptoms: Constipation-predominant IBS Quality of Supporting Evidence and d Recommendations: Three randomized clinical trials in IBS patients demonstrated a statistically significant effect in favor of linaclotide compared with placebo for constipation-predominant IBS with no significant heterogeneity between studies. There was a statistically significant effect in favor of linaclotide compared with placebo on abdominal pain but with significant heterogeneity between individual trial results. Data on overall adverse events were provided by two of the three trials. Overall, adverse event rates were not higher among those taking linaclotide compared with Placebo. However, diarrhea, reported in all three trials, was significantly more likely with linaclotide, compared with placebo Flatulence, reported in two trials, was also significantly more common with active therapy. Quality of Evidence: HIGH Lubiprostone (Selective C-2 Chloride Channel Activators) Selective C-2 chloride channel activators are effective in constipation-predominant IBS with moderate quality of evidence. Symptoms: Constipation; Overall Symptoms; Abdominal Pain Quality of Supporting Evidence and d Recommendations: Two well-designed, large clinical trials demonstrated that lubiprostone is effective in relieving IBS symptoms for women with IBS-C. It is important to note that women capable of bearing children should have documented negative pregnancy test before starting therapy and should be advised to use contraception while taking lubiprostone. Additional studies need to be conducted in men before lubiprostone can be recommended to treat male IBS symptoms. Still, lubiprostone is strongly recommended for women with IBS-C in most circumstances.

Antibiotic Therapy Antidepressants Non-absorbable antibiotics are particularly effective in diarrhea-predominant IBS with moderate quality of evidence. Symptoms: Bloating; Diarrhea; Overall Symptoms; Abdominal Pain Quality of Supporting Evidence and d Recommendations: A short term course of no-nabsorbable antibiotics is more effective than placebo (sugar pill) for improving all IBS symptoms and for bloating. More studies need to be conducted to understand the long term safety and effectiveness of non-absorbable antibiotics for the management of IBS symptoms. However, non-absorbable antibiotics are strongly recommended for short term use and can be used by most patients in most circumstances Tricyclic antidepressants and selective serotonin reuptake inhibotors (SSRIs) have been shown to be effective in IBS patients of all subtypes. The trials generally are of good quality, but the limited number of patients included in the studies means the quality of evidence was graded as moderate. ; Abdominal Pain Quality of Supporting Evidence and d Recommendations: Tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) are effective at reducing global IBS symptoms, and appear to reduce abdominal pain. The safety of using antidepressants in IBS remains poorly documented, although studies suggest that SSRIs are tolerated better than TCAs. Therefore, use of antidepressants can be strongly recommended for most patients in most circumstances. Psychological Therapies Psychological therapies may provide benefit to IBS patients, although the quality of evidence is moderate. Quality of Supporting Evidence and d Recommendations: In 20 randomized clinical trials that compared various psychological therapies with usual care, there was a benefit for cognitive behavioral therapy, dynamic psychotherapy and hypnotherapy in relieving IBS symptoms. Relaxation therapy did not show any benefit. Psychological therapies are not documented to have any serious adverse events although how and why they provide relief remains unclear. Still, use of psychological therapies can be strongly recommended for most patients in most circumstances

5-HT3 Antagonists (alosetron) for Women A class of drugs know as 5-HT3 antagonists (alosetron) is effective in IBS patients with diarrhea and the quality of evidence is good. Patients need to be carefully selected, however, because of the risk of potentially serious complications, including ischemic colitis. Symptoms: Diarrhea; Overall Symptoms; Abdominal Pain Level of Evidence: Quality of Supporting Evidence and d Recommendations: Alosetron is the only 5-HT3 receptor antagonist approved for the treatment of women with severe IBS-D in the United States. In clinical trials, potentially serious side effects including constipation and colon ischemia occurred more commonly in patients treated with alosetron than placebo (sugar pill). As a result, current use of alosetron is regulated by a prescribing program set forth by the FDA and administered by the manufacturer. Quality of Evidence: HIGH 5-HT3 Antagonists (alosetron) for Men A class of drugs know as 5-HT3 antagonists (alosetron) are effective in IBS patients with diarrhea and the quality of evidence is good. Patients need to be carefully selected, however, because of the risk of potentially serious side effects, including ischemic colitis. Symptoms: Diarrhea; Overall Symptoms Level of Evidence: Quality of Supporting Evidence and d Recommendations: In clinical studies, alosetron was shown to be effective at relieving global IBS symptoms in male IBS patients with diarrhea (IBS-D). However, potentially serious sideeffects including constipation and colon ischemia occurred more commonly in patients treated with alosetron than with placebo (sugar pill). As a result, current use of alosetron is regulated by a prescribing program set forth by the FDA and administered by the manufacturer. Probiotic Therapy Evidence suggests that some probiotics may be effective in reducing overall IBS symptoms but more data are needed. **Because of the marked differences in the probiotics evaluated in terms of study design and patient populations enrolled, the grade does not reflect the potential efficacy of specific probiotic strains or combinations, which is promising, rather it reflects the limitations of the evidence. Quality of Supporting Evidence and d Recommendations: Probiotics possess a number of properties that may prove of benefit to patients with IBS. However, probiotics vary widely in terms of species, strains, preparations and quality; making comparison of studies difficult. Lactobacilli do not appear effective for patients with IBS. Bifidobacteria and some combinations of probiotics demonstrate some efficacy for patients with IBS. According to the available safety data, probiotics are well tolerated and free from serious adverse side effects among people with IBS. Still, other treatment alternatives may be equally reasonable.

Diet There is not enough evidence that either food allergy testing or excluding certain foods from the diet is an effective treatment for IBS. Neither can be recommended. Quality of Supporting Evidence and d Recommendations: Patients often believe that certain foods make their IBS symptoms worse. However, there is not enough evidence that either food allergy testing or excluding certain foods from the diet is an effective treatment for IBS. Therefore, neither can be recommended. Bulking Agents (psyllium, hydrophilic mucilloid, ispaghula husk) Trials suggest psyllium fiber is effective in IBS patients although the quality of evidence is poor. Quality of Supporting Evidence and d Recommendations: In four out of six studies evaluated, the use of psyllium improved global IBS symptoms for some patients. It is important to note that these studies were performed many years ago and do not comply with the standards of modern study design. In addition, any adverse events as a result of using psyllium were not recorded. Still, psyllium is moderately effective for some people and can be given a conditional recommendation. However, other alternatives may be equally beneficial. Dietary Fiber Supplements (wheat or corn bran) In studies, neither wheat bran nor corn bran were effective at reducing global IBS symptoms. Neither is recommended. Quality of Supporting Evidence and d Recommendations: In studies, neither wheat bran nor corn bran were effective at reducing global IBS symptoms. Wheat bran or corn bran is not recommended for routine use. Laxatives (polyethylene glycol (PEG)) Routine use of laxatives in the treatment of IBS cannot be recommended as other alternatives may be equally reasonable. Symptoms: Stool Frequency; Abdominal Pain Quality of Supporting Evidence and d Recommendations: In one small study PEG was shown to improve stool frequency but not abdominal pain. The quality of this one study is poor and there are no additional long term, more complete studies of laxatives in IBS treatment. Therefore routine use of laxatives in the treatment of IBS cannot be recommended as other alternatives may be equally reasonable.

Antispasmodics (Hyoscine, Cimetropium, Pinaverium) Peppermint Oil Trials suggest certain antispasmodics are effective in IBS although the quality of evidence is poor. Availability of antispasmodics various greatly around the world. Quality of Supporting Evidence and d Recommendations: Many antispasmodics have demonstrated effectiveness in treating IBS, however the availability of antispasmodics varies greatly around the world. Furthermore, the research into antispasmodics differs greatly; it does not distinguish between global IBS symptoms and individual symptoms and does not provide detail of adverse events. Because there is no evidence to support the long-term effectiveness or the long term safety of antispasmodics, they cannot be recommended for routine treatment of IBS symptoms. Trials suggest that peppermint oil is effective in IBS patients although the quality of evidence is poor. Symptoms: Overall Synptoms Quality of Supporting Evidence and d Recommendations: Some peppermint oil preparations seem to be effective at relieving IBS symptoms, however, preparations and quality vary greatly. Because there is no evidence to support the long-term effectiveness or the long term safety of using peppermint oil preparations, they cannot be recommended for routine treatment of IBS symptoms. Antidiarrheal Agents (loperamide) Antidiarrheals reduce the frequency of stools but do not affect the overall symptoms of IBS. Symptoms: Diarrhea; Abdominal Pain; Bloating; Overall Symptoms Quality of Supporting Evidence and d Recommendations: In clinical studies, the antidiarrheal agent loperamide was no more effective than placebo (sugar pill) at reducing pain, bloating or global symptoms of IBS. However loperamide is effective in treating diarrhea, reducing stool frequency and improving stool consistency. No clinical trials have been performed comparing loperamide with other antidiarrheal agents and loperamide has not been broadly tested in terms of safety and long term tolerance. Still, loperamide can be considered an effective therapy for diarrhea.

Herbal Therapies and Acupuncture Further study is needed before any recommendations on acupuncture or herbal therapy can be made. Symptoms: N/A Level of Evidence: Ø Quality of Supporting Evidence and d Recommendations: Although the available clinical studies of unique Chinese herbal mixtures appear to show benefit, it is not possible to compare these studies. Any benefit from Chinese herbal therapy in IBS is suspect due to the variations in purity and the components used in each mixture. There are significant concerns about toxicity, especially lifer failure, with the use of any Chinese herbal mixture. A review of acupuncture trials was inconclusive. Further study is needed before any recommendations on acupuncture or herbal therapy can be made. Recommendation: NONE Quality of Evidence: N/A The American College of Gastroenterology (ACG) evaluated a broad spectrum of medical research and conducted a rigorous review of the evidence regarding the effectiveness of testing and treatments for IBS. The results were graded by physician experts based on the quality of the scientific studies, including study design and findings and published in The American Journal of Gastroenterology in January 2009. The IBS Treatment Matrix was developed based on this evidence-based review. Each studied IBS treatment is graded according to the quality of the scientific evidence supporting its use and its safety and effectiveness at treating overall IBS symptoms. Reviewed by Brian Lacy, MD, FACG 3/18/2014